Rocket Pharmaceuticals announces strategic collaboration with Stanford Medical
Rocket Pharmaceuticals and the Stanford University School of Medicine announced a strategic collaboration to support the advancement of Fanconi Anemia, or FA, and Pyruvate Kinase Deficiency, or PKD, gene therapy research. Rocket's lentiviral vector, or LVV-based gene therapy program for FA is currently in clinical trials with academic partners in the U.S. and Europe. The LVV-based gene therapy program for PKD is currently in preclinical development in Europe. Under the terms of the agreement, Stanford will serve as a lead clinical trial research center in the United States for a planned upcoming registrational trial for FA, and would also be the lead site for PKD clinical trials. Maria Grazia Roncarolo will lead the school's effort. The center is a joint initiative of the School of Medicine, Stanford Health Care and Stanford Children's Health and is focused on bench to bedside development of innovative cell- and gene-based therapies.